• 1
    Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973; 136: 40916.
  • 2
    Warkentin TE. History of heparin-induced thrombocytopenia. In: WarkentinTE, GreinacherA, eds. Heparin-Induced Thrombocytopenia, 4th edn. New York: Informa Healthcare USA, 2007: 119.
  • 3
    Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 17.
  • 4
    Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 92530.
  • 5
    Chong BH, Fawaz I, Chestermann CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 23540.
  • 6
    Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996; 52: 905.
  • 7
    Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 17038.
  • 8
    Warkentin TE, Sheppard JI, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 3416.
  • 9
    Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005; 106: 29212.
  • 10
    Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJH. Prospective evaluation of immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 12605.
  • 11
    Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82: 103743.
  • 12
    Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 3815.
  • 13
    Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 2730.
  • 14
    Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 3719.
  • 15
    Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 130412.
  • 16
    Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 13305.
  • 17
    Warkentin TE, Davidson BL, Büller HR, Gallus A, Gent M, Lensing AWA, Piovella F, Prins MH, Segers AEM, Kelton JG. Prevalence and risk of pre-existing heparin-induced thrombocytopenia antibodies in patients with acute venous thromboembolism. Chest 2011. [Epub ahead of print 10 March 2011].
  • 18
    Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 251824.
  • 19
    Warkentin TE, Cook RJ. Impact of laboratory testing for heparin-induced antibodies: using Bayes’ rule to prevent overdiagnosis of heparin-induced thrombocytopenia. [Bedeutung von Laboruntersuchungen von Heparin-induzierten Antikörpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Prävention der Überdiagnose einer Heparin-induzierten Thrombozytopenie]. J Lab Med 2011; 35: 4554.
  • 20
    Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 7346.
  • 21
    Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 956.
  • 22
    Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 32329.
  • 23
    Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 24751.
  • 24
    Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 818.
  • 25
    Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: WarkentinTE, GreinacherA, eds. Heparin-Induced Thrombocytopenia, 4th edn. New York: Informa Healthcare USA, 2007: 67116.
  • 26
    Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 9549.
  • 27
    Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997; 54: 196201.
  • 28
    Amiral J, Pouplard C, Vissac AM, Walenga JM, Jeske W, Gruel Y. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 2000; 109: 33641.
  • 29
    Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, Seligsohn U. False-positive tests for heparin induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009; 7: 10704.
  • 30
    Greinacher A, Ittermann T, Bagemühl J, Althaus K, Fürll B, Selleng S, Lubenow N, Schellong S, Sheppard JI, Warkentin TE. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 2010; 8: 202531.
  • 31
    Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 88690.
  • 32
    Warkentin TE, Sheppard JI, Moore JC, Kelton JG. The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8: 2168.
  • 33
    Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010; 116: 17616.
  • 34
    Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4: 2812.
  • 35
    Bakchoul T, Giptner A, Bein G, Santoso S, Sachs UJH. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011; 127: 3458.
  • 36
    Althaus K, Strobel U, Warkentin TE, Greinacher A. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 2011. [Epub ahead of print 25 May 2011].
  • 37
    Warkentin TE, Sheppard JI, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 49639.
  • 38
    Greinacher A, Kohlmann T, Strobel U, Sheppard JI, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 49706.
  • 39
    Warkentin TE, Sheppard JI. Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin-induced thrombocytopenia (HIT). J Thromb Haemost 2007; 5: 6367.
  • 40
    Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008; 29: 6674.
  • 41
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 128692.
  • 42
    Smythe MA, Warkentin TE, Woodhouse AL, Zakalik D. Venous limb gangrene and fatal hemorrhage: adverse consequences of HIT “overdiagnosis” in a patient with antiphospholipid syndrome. Am J Hematol 2011; 86: 18891.
  • 43
    Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5: 166673.
  • 44
    Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest 2011; 139: 2718.
  • 45
    Selleng S, Malowsky B, Strobel U, Wessel A, Ittermann T, Wollert HG, Warkentin TE, Greinacher A. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia even when antibody tests are positive. J Thromb Haemost 2010; 8: 306.
  • 46
    Selleng S, Selleng K, Wollert HG, Muellejans B, Lietz T, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 2008; 6: 42835.
  • 47
    Warkentin TE, Sheppard JI, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2005; 108: 293741.
  • 48
    Warkentin TE, Cook RJ, Marder VJ, Sheppard JI, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 37916.
  • 49
    Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A, Jünger M, Nauck M, Schellong S, Wander K, Engel G, Ekkernkamp A, Greinacher A. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115: 1797803.
  • 50
    Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation post-orthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 2010; 8: 50412.
  • 51
    Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: WarkentinTE, GreinacherA, eds. Heparin-Induced Thrombocytopenia, 4th edn. New York: Informa Healthcare USA, 2007: 2166.
  • 52
    Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 6576.
  • 53
    Chesterman CN, McGready JR, Doyle DJ, Morgan FJ. Plasma factors of platelet factor 4 measured by radioimmunoassay. Br J Haematol 1978; 40: 489500.
  • 54
    Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008; 122: 21120.
  • 55
    Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006; 107: 234653.
  • 56
    Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121: 6326.
  • 57
    Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT? J Thromb Haemost 2008; 6: 1598600.
  • 58
    Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery ‘spontaneous’ HIT? J Thromb Haemost 2009; 7: 499501.
  • 59
    Mallik A, Carlson KB, DeSancho MT. A patient with ‘spontaneous’ heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagul Fibrinolysis 2011; 22: 735.
  • 60
    Krauel K, Pötschke C, Weber C, Kessler W, Fürll B, Ittermann T, Maier S, Hammerschmidt S, Bröker BM, Greinacher A. Platelet factor 4 binds to bacteria – inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117: 13708.
  • 61
    Greinacher A, Holtfreter B, Krauel K, Gätke D, Weber C, Itterman T, Hammerschmidt S, Kocher T. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood. [Epub ahead of print 9 June 2011].
  • 62
    Matsuo T, Tomaru T, Kario K, Hirokawa T, HIT Research Group of Japan. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res 2005; 115: 47581.
  • 63
    Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 5027.
  • 64
    Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003; 110: 7382.
  • 65
    Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 36919.
  • 66
    Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets 1999; 10: 31926.
  • 67
    Tardy-Poncet B, Piot M, Chapelle C, France G, Campos L, Garraud O, Decousus H, Mismetti P, Tardy B. Thrombin generation and heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 147481.
  • 68
    Rauova L, Hirsch JD, Greene TK, Zhai L, Hayes VM, Kowalska MA, Cines DB, Poncz M. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010; 116: 502131.
  • 69
    Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 5819.
  • 70
    Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 80412.
  • 71
    Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, Murphy S, Baker KR. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164: 6670.
  • 72
    Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996; 10: 24958.
  • 73
    Kowalska MA, Rauova L, Hayes V, Cines DB, Bougie DW, Aster RH, Krishnaswamy S, Poncz M. Heparin-induced thrombocytopenia antibodies inhibit PF4-dependent enhancement of activated protein C formation by binding to antigenic complexes formed with the chondroitin sulfate side-chain of thrombomodulin. Blood 2010; 116 (Suppl.): 318 (Abstract).
  • 74
    Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 5026.
  • 75
    Rice L, Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136: 2105.
  • 76
    Prechel MM, McDonald MK, Jeske WP, Messmore HL, Walenga JM. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 2005; 3: 216875.
  • 77
    Socher I, Kroll H, Jorks S, Santoso S, Sachs UJ. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence. J Thromb Haemost 2008; 6: 197200.
  • 78
    Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real world issues. Semin Thromb Hemost 2011; in press.
  • 79
    Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 81929.
  • 80
    Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2010; 24: 75575.
  • 81
    Salmela B, Joutsi-Korhonen L, Saarela E, Lassila R. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. Thromb Res 2010; 125: 53844.
  • 82
    Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98: 23442.
  • 83
    Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. A clinical outcome study. Thromb Haemost 2001; 86: 11705.
  • 84
    Lubenow N, Warkentin TE, Greinacher A, Wessel A, Sloane DA, Krahn EL, Magnani HN. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006; 117: 50715.
  • 85
    Kuo KHM, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005; 93: 9991000.
  • 86
    Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 20814.
  • 87
    Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2010; 16: 6637.
  • 88
    Warkentin TE. Fondaparinux: does it cause HIT? can it treat HIT? Expert Rev Hematol 2010; 3: 56781.
  • 89
    Motokawa S, Torigoshi T, Maeda Y, Maeda K, Jiuchi Y, Yamaguchi T, Someya S, Shindo H, Migita K. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord 2011; 12: 22 [Epub ahead of print].
  • 90
    Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 26534.
  • 91
    Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 77981.
  • 92
    Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost 2010; 104: 10712.
  • 93
    Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 13944.
  • 94
    Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost 2008; 6: 12436.
  • 95
    Warkentin TE, Pai M, Schulman S, Spyropoulos A, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia (HIT) confirmed by a positive serotonin-release assay (SRA+). J Thromb Haemost 2011; in press (Abstract).
  • 96
    Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 6 (Suppl.): 340S80S.
  • 97
    Hartman V, Malbrain M, Daelemans R, Meersman P, Zachée P. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 2006; 104: c1438.
  • 98
    Wanaka K, Matsuo T, Matsuo M, Kaneko C, Miyashita K, Asada R, Matsushima H, Nakajima Y. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8: 6168.
  • 99
    Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B. Fatal effect of reexposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 1990; 336: 10778.
  • 100
    Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343: 515.